Filing Flows › RxSight (RXST) › Q4 2025
RxSight (RXST) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 25, 2026
RxSight (RXST) reported revenue of $32.6M for the fourth quarter 2025 (Q4 2025), -19% from a year earlier and +7% from the quarter before. Operating margin was -34.8%, net loss $9.2M (28.1% of revenue).
RxSight, Q4 2025: revenue $32.6M (-19% year over year), operating margin -34.8%, net loss $9.2M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.6M | +7% | -19% |
| Operating profit | −$11.3M | — | — |
| Net earnings | −$9.2M | — | — |
| Operating cash flow | −$1.1M | — | — |
What changed
Revenue was $32.6M in Q4 2025, down 19% year over year and up 7% from the previous quarter. Rxlal was the largest line at 86% of revenue.
Gross margin was 77.5%, up 5.9 points from a year earlier. Operating costs exceeded revenue by $11.3M, an operating margin of -34.8%. Operating expenses fell 2% while revenue fell 19%. The quarter ended with a net loss of $9.2M, narrower than the previous quarter's $9.8M loss. Non-operating items added $2.2M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.1M. Non-cash charges added back $851K of depreciation and amortization and $7.8M of share-based compensation. Working capital and other items used $632K. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$2.3M.
Questions
What was RxSight's revenue in the fourth quarter 2025?
RxSight (RXST) reported revenue of $32.6M for the fourth quarter 2025 (Q4 2025), -19% from a year earlier and +7% from the quarter before.
Was RxSight profitable in the fourth quarter 2025?
Operating loss was $11.3M (-34.8% of revenue) and net loss $9.2M.
Source: RxSight 10-K on SEC EDGAR.